Table 4.
Univariate analysis of patients infected with H1N1pdm 6B.2 variant 1 and 6B.2 variant 2 viruses of Baltimore and Northern Taiwan in the 2015–16 season.
| Characteristic | 6B.2 Variant-1 (n = 6) N (%)/median (IQR) | 6B.2 Variant-2 (n = 13) N (%)/median (IQR) | P value |
|---|---|---|---|
| Demographics | |||
| Site | |||
| JHMI | 0 (0) | 0 (0) | 0.99 |
| CGMH | 6 (100.0) | 13 (100.0) | |
| Age | |||
| In years | 34 (29–48) | 44 (34–54) | 0.20a |
| 18–49 | 4 (66.7) | 8 (61.5) | 0.99 |
| 50–64 | 2 (33.3) | 5 (38.5) | 0.99 |
| 65+ | 0 (0) | 0 (0) | 0.99 |
| Gender | |||
| Female | 3 (50.0) | 11 (84.6) | 0.26 |
| Male | 3 (50.0) | 2 (15.4) | |
| Ethnicity | |||
| Non-Hispanic or Latino | 6 (100.0) | 13 (100.0) | 0.99 |
| Hispanic or Latino | 0 (0) | 0 (0) | |
| Race | |||
| Black or African American | 0 (0) | 0 (0) | 0.99 |
| White | 0 (0) | 0 (0) | 0.99 |
| Asian | 6 (100.0) | 13 (100.0) | 0.99 |
| Other | 0 (0) | 0 (0) | 0.99 |
| Vaccination and exposure | |||
| Human exposure | 0 (0) | 2 (15.4) | 0.83 |
| Travel in last 30 days | 3 (50.0) | 3 (23.1) | 0.32 |
| Influenza vaccine | 0 (0) | 0 (0) | 0.99 |
| Co-morbidities and high risk | |||
| No co-morbidities | 3 (50.0) | 4 (30.8) | 0.77 |
| One co-morbidity | 2 (33.3) | 6 (46.2) | 0.99 |
| Multiple co-morbidities | 1 (16.7) | 3 (23.1) | 0.99 |
| Immunosuppressive medication | 0 (0) | 0 (0) | 0.99 |
| Pregnant | 0 (0) | 0 (0) | 0.99 |
| Disease severity | |||
| NEWS score | 4 (2–6) | 3 (0–5) | 0.54a |
| Oxygen supplementation | 0 (0) | 3 (23.1) | 0.52 |
| BiPAP/CPAP | 0 (0) | 0 (0) | 0.99 |
| Intubated | 0 (0) | 0 (0) | 0.99 |
| Pneumonia | 2 (33.3) | 5 (38.5) | 0.99 |
| Admitted or observation | 0 (0) | 2 (15.4) | 0.99 |
| LOS | 0 (0 –0) | 10.0 (5 –15) | <0.01* |
| ICU | 0 (0) | 0 (0) | 0.99 |
| Death | 0 (0) | 0 (0) | 0.99 |
| Follow-up due to sequala | 0 (0) | 1 (7.7) | 0.99 |
| Viral co-infection | 0 (0) | 0 (0) | 0.99 |
| Symptoms | |||
| Fever | 6 (100.0) | 13 (100.0) | 0.99 |
| Cough | 6 (100.0) | 13 (100.0) | 0.99 |
| Sputum | 5 (83.3) | 9 (69.2) | 0.99 |
| Increased sputum | 3 (50.0) | 3 (23.1) | 0.32 |
| Shortness of breath | 2 (33.3) | 8 (61.5) | 0.35 |
| Wheezing | 2 (33.3) | 8 (61.5) | 0.35 |
| Headache | 6 (100.0) | 12 (92.3) | 0.99 |
| Sore throat | 6 (100.0) | 9 (69.2) | 0.26 |
| Body aches | 6 (100.0) | 13 (100.0) | 0.99 |
| Runny nose | 6 (100.0) | 13 (100.0) | 0.99 |
| Sinus pain | 0 (0) | 1 (7.7) | 0.99 |
| Fatigue | 6 (100.0) | 12 (92.3) | 0.99 |
| Chest pain | 2 (33.3) | 6 (46.2) | 0.99 |
| Chills | 5 (83.3) | 11 (84.6) | 0.99 |
| Loss of appetite | 6 (100.0) | 10 (76.9) | 0.52 |
| Nausea/vomiting | 3 (50.0) | 9 (69.2) | 0.62 |
| Diarrhea | 4 (66.7) | 5 (38.5) | 0.35 |
| Conjunctivitis | 0 (0) | 2 (15.4) | 0.99 |
Statistical analysis was done using R software.
Categorical variables were compared using Chi-square or Fisher's exact tests.
a
Continuous variables were compared with rank-sum test.
*
Statistical significance was set at p < 0.05 and was represented in Bold and Italics.